News | November 15, 2022
SMS Pharma revenue down 9%
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
The company increases its efficiency and is able to face the growing demand for its services.
Subscribe To Our Newsletter & Stay Updated
